Distinct Clinical Outcomes and Biological Features of Specific KRAS Mutants in Human Pancreatic Cancer

Clinical Outcomes and Biological Characteristics Study Report for Pancreatic Cancer Patients with KRAS Mutations Research Background and Objective Pancreatic Ductal Adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. Only about 20% of PDAC patients are eligible for resection surgery, thus the five-year sur...

Clinical Impact of Preemptive Pharmacogenomic Testing on Antiplatelet Therapy in a Real-World Setting

Clinical Impact of Pharmacogenomic Testing on Antiplatelet Therapy Background Pharmacogenomics (PGx) is changing the use of P2Y12 inhibitors (antiplatelet drugs), which are widely used in the treatment of acute coronary syndrome (ACS), neurovascular problems, and vascular diseases. Among them, clopidogrel is a commonly used P2Y12 inhibitor. This pr...